Vigil Neuroscience Net Worth
Vigil Neuroscience Net Worth Breakdown | VIGL |
Vigil Neuroscience Net Worth Analysis
Vigil Neuroscience's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vigil Neuroscience's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vigil Neuroscience's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vigil Neuroscience's net worth analysis. One common approach is to calculate Vigil Neuroscience's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vigil Neuroscience's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vigil Neuroscience's net worth. This approach calculates the present value of Vigil Neuroscience's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vigil Neuroscience's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vigil Neuroscience's net worth. This involves comparing Vigil Neuroscience's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vigil Neuroscience's net worth relative to its peers.
Enterprise Value |
|
To determine if Vigil Neuroscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vigil Neuroscience's net worth research are outlined below:
| Vigil Neuroscience is way too risky over 90 days horizon | |
| Vigil Neuroscience appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (84.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vigil Neuroscience currently holds about 148.91 M in cash with (51.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.27. | |
| Vigil Neuroscience has a frail financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from globenewswire.com: SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates CHTR, TASK, VIGL, STRM on Behalf of Shareholders |
Vigil Neuroscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vigil Neuroscience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vigil Neuroscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Vigil Neuroscience Target Price Consensus
Vigil target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Vigil Neuroscience's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Hold |
Most Vigil analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Vigil stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Vigil Neuroscience, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVigil Neuroscience Target Price Projection
Vigil Neuroscience's current and average target prices are 8.08 and 9.52, respectively. The current price of Vigil Neuroscience is the price at which Vigil Neuroscience is currently trading. On the other hand, Vigil Neuroscience's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Vigil Neuroscience Market Quote on 21st of July 2025
Target Price
Analyst Consensus On Vigil Neuroscience Target Price
Know Vigil Neuroscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vigil Neuroscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vigil Neuroscience backward and forwards among themselves. Vigil Neuroscience's institutional investor refers to the entity that pools money to purchase Vigil Neuroscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2025-03-31 | 419.1 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2025-03-31 | 289.5 K | Woodline Partners Lp | 2025-03-31 | 252.8 K | Ikarian Capital, Llc | 2025-03-31 | 250 K | Geode Capital Management, Llc | 2025-03-31 | 244.5 K | Renaissance Technologies Corp | 2025-03-31 | 219.4 K | Susquehanna International Group, Llp | 2025-03-31 | 212.6 K | Trustees Of Columbia University In The City Of New York | 2025-03-31 | 193 K | Squarepoint Ops Llc | 2025-03-31 | 111 K | Bvf Inc | 2025-03-31 | 4 M | Siren, L.l.c. | 2025-03-31 | 2 M |
Follow Vigil Neuroscience's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 376.64 M.Market Cap |
|
Project Vigil Neuroscience's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.72) | (0.75) | |
| Return On Capital Employed | (1.07) | (1.13) | |
| Return On Assets | (0.72) | (0.75) | |
| Return On Equity | (1.18) | (1.12) |
When accessing Vigil Neuroscience's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vigil Neuroscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vigil Neuroscience's profitability and make more informed investment decisions.
Evaluate Vigil Neuroscience's management efficiency
Vigil Neuroscience has return on total asset (ROA) of (0.4938) % which means that it has lost $0.4938 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.027) %, meaning that it created substantial loss on money invested by shareholders. Vigil Neuroscience's management efficiency ratios could be used to measure how well Vigil Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.75. The value of Return On Capital Employed is expected to slide to -1.13. At this time, Vigil Neuroscience's Other Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.12 this year, although the value of Return On Tangible Assets will most likely fall to (0.75).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.76 | 1.85 | |
| Tangible Book Value Per Share | 1.76 | 1.85 | |
| Enterprise Value Over EBITDA | (0.51) | (0.54) | |
| Price Book Value Ratio | 0.97 | 1.01 | |
| Enterprise Value Multiple | (0.51) | (0.54) | |
| Price Fair Value | 0.97 | 1.01 | |
| Enterprise Value | 43.1 M | 40.9 M |
At Vigil Neuroscience, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vigil Neuroscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vigil Neuroscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vigil Neuroscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vigil Neuroscience Corporate Filings
8K | 17th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of June 2025 Other Reports | ViewVerify | |
| 16th of June 2025 Other Reports | ViewVerify | |
| 12th of June 2025 Other Reports | ViewVerify |
Vigil Neuroscience Earnings Estimation Breakdown
The calculation of Vigil Neuroscience's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vigil Neuroscience is estimated to be -0.484175 with the future projection ranging from a low of -0.5175 to a high of -0.4525. Please be aware that this consensus of annual earnings estimates for Vigil Neuroscience is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.52 Lowest | Expected EPS | -0.45 Highest |
Vigil Neuroscience Earnings Projection Consensus
Suppose the current estimates of Vigil Neuroscience's value are higher than the current market price of the Vigil Neuroscience stock. In this case, investors may conclude that Vigil Neuroscience is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vigil Neuroscience's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 8 | 85.15% | 0.0 | -0.484175 | -2.06 |
Vigil Neuroscience Earnings per Share Projection vs Actual
Actual Earning per Share of Vigil Neuroscience refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vigil Neuroscience predict the company's earnings will be in the future. The higher the earnings per share of Vigil Neuroscience, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Vigil Neuroscience Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Vigil Neuroscience, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vigil Neuroscience should always be considered in relation to other companies to make a more educated investment decision.Vigil Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Vigil Neuroscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-07 | 2025-03-31 | -0.5298 | -0.49 | 0.0398 | 7 | ||
2025-03-13 | 2024-12-31 | -0.54 | -0.57 | -0.03 | 5 | ||
2024-11-07 | 2024-09-30 | -0.5447 | -0.47 | 0.0747 | 13 | ||
2024-08-13 | 2024-06-30 | -0.55 | -0.52 | 0.03 | 5 | ||
2024-05-07 | 2024-03-31 | -0.5 | -0.5 | 0.0 | 0 | ||
2024-03-26 | 2023-12-31 | -0.53 | -0.57 | -0.04 | 7 | ||
2023-11-07 | 2023-09-30 | -0.57 | -0.53 | 0.04 | 7 | ||
2023-08-08 | 2023-06-30 | -0.54 | -0.52 | 0.02 | 3 | ||
2023-05-10 | 2023-03-31 | -0.53 | -0.51 | 0.02 | 3 | ||
2023-03-21 | 2022-12-31 | -0.58 | -0.48 | 0.1 | 17 | ||
2022-11-10 | 2022-09-30 | -0.6 | -0.53 | 0.07 | 11 | ||
2022-08-08 | 2022-06-30 | -0.67 | -0.6 | 0.07 | 10 | ||
2022-05-12 | 2022-03-31 | -0.58 | -0.58 | 0.0 | 0 | ||
2022-01-10 | 2021-12-31 | -0.7833 | -8.28 | -7.4967 | 957 | ||
2021-10-08 | 2021-09-30 | -0.5 | -0.15 | 0.35 | 70 |
Vigil Neuroscience Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Spyridon MD | Chief Officer | Profile | |
| Weeteck Yeo | Senior Operations | Profile | |
| Jessica PMP | Senior Management | Profile | |
| Mr DABT | Senior Development | Profile | |
| Christopher JD | General Secretary | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.